CBIC CIC Questions Answers

The CBIC Certified Infection Control Exam Study Guide (6th edition) identifies the randomized clinical trial (RCT) as the study design that provides the strongest evidence of a causal relationship between a risk factor (or intervention) and an outcome. RCTs are considered the gold standard because they use random assignment to allocate participants to either an intervention group or a control group, which minimizes bias and balances both known and unknown confounding variables between groups.

By controlling exposure and randomly assigning participants, RCTs establish temporality, ensuring that the exposure precedes the outcome—an essential criterion for causality. This design also allows for direct comparison of outcomes under controlled conditions, making it possible to attribute observed differences in outcomes to the intervention or risk factor with a high degree of confidence.

In contrast, cohort studies and case-control studies are observational and can identify associations but are more susceptible to confounding and bias. While cohort studies can demonstrate temporal relationships and estimate risk, they cannot control exposures as precisely as RCTs. Case-control studies are particularly vulnerable to recall and selection bias. Cross-sectional studies assess exposure and outcome simultaneously and cannot establish causation.

For the CIC® exam, it is critical to recognize that randomized clinical trials offer the highest level of evidence for causality, particularly when evaluating interventions, preventive measures, or treatment effectiveness in infection prevention and healthcare epidemiology.

The scenario involves a surgical patient with a purulent abdominal wound culture growing Staphylococcus aureus, a common pathogen in surgical site infections (SSIs). The Certification Board of Infection Control and Epidemiology (CBIC) emphasizes accurate interpretation of culture results and antibiotic therapy in the "Identification of Infectious Disease Processes" and "Prevention and Control of Infectious Diseases" domains, aligning with the Centers for Disease Control and Prevention (CDC) guidelines for managing SSIs. The question requires assessing the sensitivity pattern and current treatment to determine the correct statement.

Option B, "The current therapy is not effective," is true. The wound culture shows Staphylococcus aureus resistant to oxacillin, indicating methicillin-resistant S. aureus (MRSA). The sensitivity pattern lists resistance to penicillin, oxacillin, cephalothin, and erythromycin, with susceptibility to clindamycin and vancomycin. Cefazolin, a first-generation cephalosporin, is ineffective against MRSA because resistance to oxacillin (a penicillinase-resistant penicillin) implies cross-resistance to cephalosporins like cefazolin due to altered penicillin-binding proteins (PBPs). The CDC’s "Guidelines for the Prevention of Surgical Site Infections" (2017) and the Clinical and Laboratory Standards Institute (CLSI) standards confirm that MRSA strains are not susceptible to cefazolin, meaning the current therapy is inappropriate and unlikely to resolve the infection, supporting Option B.

Option A, "The wound is not infected," is incorrect. The presence of purulent drainage, a clinical sign of infection, combined with a positive culture for S. aureus, confirms an active wound infection. The CBIC and CDC define purulent discharge as a key indicator of SSI, ruling out this statement. Option C, "Droplet Precautions should be initiated," is not applicable. Droplet Precautions are recommended for pathogens transmitted via respiratory droplets (e.g., influenza, pertussis), not for S. aureus, which is primarily spread by contact. The CDC’s "Guideline for Isolation Precautions" (2007) specifies Contact Precautions for MRSA, not Droplet Precautions, making this false. Option D, "This is a methicillin-sensitive S. aureus (MSSA) strain," is incorrect. Methicillin sensitivity is determined by susceptibility to oxacillin, and the resistance to oxacillin in the culture result classifies this as MRSA, not MSSA. The CDC and CLSI use oxacillin resistance as the defining criterion for MRSA.

The CBIC Practice Analysis (2022) and CDC guidelines stress the importance of aligning antimicrobial therapy with sensitivity patterns to optimize treatment outcomes. The mismatch between cefazolin and the MRSA sensitivity profile confirms that Option B is the correct statement, indicating ineffective current therapy.

The correct answer is C, "sterilizer identification number or code," as this is the essential information that each item or package prepared for sterilization should be labeled with. According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, proper labeling of sterilized items is a critical component of infection prevention and control to ensure traceability and verify the sterilization process. The sterilizer identification number or code links the item to a specific sterilization cycle, allowing the infection preventionist (IP) and sterile processing staff to track the equipment used, confirm compliance with standards (e.g., AAMI ST79), and facilitate recall or investigation if issues arise (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.3 - Ensure safe reprocessing of medical equipment). This labeling ensures that the sterility of the item can be assured and documented, protecting patient safety by preventing the use of inadequately processed items.

Option A (storage location) is important for inventory management but is not directly related to the sterilization process itself and does not provide evidence of the sterilization event. Option B (type of sterilization process) indicates the method (e.g., steam, ethylene oxide), which is useful but less critical than the sterilizer identification, as the process type alone does not confirm the specific cycle or equipment used. Option D (cleaning method, e.g., mechanical or manual) is a preliminary step in reprocessing, but it is not required on the sterilization label, as the focus shifts to sterilization verification once the item is prepared.

The requirement for a sterilizer identification number or code aligns with CBIC’s emphasis on maintaining rigorous tracking and quality assurance in the reprocessing of medical devices, ensuring accountability and adherence to best practices (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.5 - Evaluate the environment for infection risks). This practice is mandated by standards such as AAMI ST79 to support effective infection control in healthcare settings.

A safety culture with reciprocal accountability emphasizes mutual responsibility for maintaining safe practices, encouraging staff at all levels to "speak up" or "stop the line" when they observe risky practices. This concept reflects a learning organization and a just culture that supports open communication and proactive risk mitigation.

According to the APIC Text, a strong safety culture is described as one where:

“The leadership can expect staff members to call out or stop the line when they see risk, and staff can expect leadership to listen and act.”

This dynamic reflects reciprocal accountability.

Other options are less accurate:

A. Human factors refer to system design, not behavioral accountability.

B. Honest disclosure of a safety event is about post-event transparency, not real-time intervention.

C. A blaming and shaming culture is antithetical to safety culture principles.